firstwordpharma.com
Lilly's Omvoh scores second IBD win with FDA nod in Crohn's - FirstWord Pharma
Cure8 flagged this item because the article title and available source metadata connect it to Crohn's disease, Inflammatory bowel disease, Mirikizumab, and IL-23 inhibitor. We do not yet have enough reliable article text to summarize the details.
This may be most useful for Adult patients following Crohn's disease, Inflammatory bowel disease, Mirikizumab, IL-23 inhibitor, and Medications.
What To Know
Cure8 does not have enough reliable source text to summarize this article yet. Based on the article title and source metadata, this appears to be a regulatory update related to Crohn's disease, Inflammatory bowel disease, Mirikizumab, and IL-23 inhibitor. Use the original source link for the full details.
The original article from firstwordpharma.com has the full details, including any study limitations or source context.
